Semaglutide, tirzepatide, and other GLP-1 agonists all increase risk proportional to the speed of fat loss
Clinical studies and translational investigations have reported changes in body weight, adiposity measures, and related metabolic markers, supporting the use of retatrutide as a research tool for examining multi-receptor regulation of adipose tissue biology and systemic metabolic signaling [2][3][5]
Some already lost access
Theyre tools, and like any tool, they work best when used properly and consistently
Understanding patients perspectives and experiences can guide the development of supportive interventions and educational resources
That mainstream attention has filtered straight into gyms, fitness influencer feeds, and trainer certification courses